Who we are

About Aspen

We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability, positioning us well to maximise the value we create for our business and our diverse stakeholders.

Approximately

9 800

employees in 71 offices in over 50 countries

    49%

Women

   

Our geographic footprint

Headquartered in South Africa, Aspen is a global specialty and branded pharmaceutical company with a presence in both emerging and developed markets.

  60%

of Commercial Pharmaceutical revenue from emerging markets

51%

Men

 

Our business segments

We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments.

Commercial Pharmaceuticals         Manufacturing  

Regional Brands – a widely diverse segment comprising predominantly leading domestic brands in the Sub‑Saharan Africa, Australasia and Latin American territories

Contribution to Group revenue
44%
       

Contract and upply of chemical and biochemical active pharmaceutical ingredients (“APIs”) and finished dose form (“FDF”) pharmaceuticals for third parties.

Contribution to
Group revenue

19%
 

Sterile Focus Brands – focused on niche, sterile products comprising our Anaesthetics Brands and Thrombosis Brands.

         
 

Anaesthetics – includes a broad range of general anaesthetics, muscle relaxants as well as a number of local anaesthetics including topical agents.

Contribution to Group revenue
37%
        Total revenue
R38,6 billion
continuing operations
 
 

Thrombosis – comprises a broad range of specialist injectable anticoagulants with a focus on low molecular weight heparins, Xainhibitors and heparin derivatives.

             
                   

 

 

Our strategic objectives

Our strategic objectives provide the foundation for our plan of action to achieve our short-, medium- and long-term goals.

To deliver a differentiated portfolio of high quality and affordable medicines to improve the health and quality of life of patients
To optimise the strategic advantage of our integrated value chain
To develop and retain a talented, agile and diverse workforce inspired to achieve operational excellence
To be a good corporate citizen by conducting our business in a responsible, inclusive and sustainable way
To create sustainable economic value for all of our stakeholders
     

 

7

Active pharmaceutical ingredient facilities

   

Our manufacturing capabilities

Our manufacturing capabilities span a wide variety of product types including steriles, oral solid dose, liquids, semisolids, biologicals and APIs. Our manufacturing sites hold international approvals from some of the most stringent global regulatory agencies.

   

FTSE4Good and FTSE/JSE Top 30 Responsible Investment Index constituent

 

Our commitment to sustainability

We are committed to creating value for all of our stakeholders in a manner that is responsible, transparent and respects the rights of all.

16

Finished dose form facilities